[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500944":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":61,"collaborators":65,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":10,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Goethe University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Inhibitor negative, FVIII on demand or regularly",null,"Patients with severe hemophilia A receiving emicizumab therapy which are negative for factor VIII Inhibitor (including patients post ITI) and are receiving factor VIII therapy either on demand or regularly,",[13],"Other: no interventions",{"label":15,"type":10,"description":16,"interventionNames":17},"Inhibitor positive, FVIII therapy regularly (ITI)","Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving regularly factor VIII therapy (ITI)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Inhibitor positive, no FVIII therapy","Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving no factor VIII therapy",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"no interventions","no intervention, only 3 different patients groups",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Christoph Koenigs, PD Dr. Dr","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Stephan Schultze-Strasser, Dr.","CONTACT","+496963016998","stephan.schultze-strasser@kgu.de",{"name":29,"role":34,"phone":38,"phoneExt":10,"email":39},"+4969630183030","christoph.koenigs@kgu.de",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Hospital Frankfurt, Goethe University","RECRUITING","Frankfurt am Main","Hesse","60590","Germany","DE",{"type":50,"coordinates":51},"Point",[52,53],8.68417,50.11552,{"lat":53,"lon":52},[56,58],{"name":33,"role":34,"phone":57,"phoneExt":10,"email":36},"00496963016998",{"name":59,"role":34,"phone":60,"phoneExt":10,"email":39},"Christoph Koenigs, PD Dr. Dr.","004969630183030",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Christoph Königs","Principal Investigator, Head of molecular and clinical Haemostasis",[66,69],{"name":67,"class":68},"Roche Pharma AG","INDUSTRY",{"name":70,"class":71},"Chugai Pharma Germany GmbH","UNKNOWN","100500944","dynamics-of-the-anti-factor-viii-antibody-signature-during-treatment-with-emicizumab-100500944",false,"NCT05802836","Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab","NAVIGATE","Inclusion Criteria:\n\n* Severe congenital hemophilia A (CHA)\n* Treatment with emicizumab irrespective of any other treatment\n* Informed consent\n\nExclusion Criteria:\n\n* No therapy with emicizumab\n* Immunosuppressive therapy\n* HIV-infection with CD4 (cluster of differentiation 4) cells \\\u003C200\u002Fµl","ALL",{"count":81,"type":82},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.",[86,87,88],"Severe Hemophilia A","Severe Hemophilia A With Inhibitor","Severe Hemophilia A Without Inhibitor","2023-07-07",{"date":91,"type":92},"2023-07-10","ACTUAL",{"date":94,"type":92},"2023-04-26",{"date":96,"type":82},"2029-12",{"name":63,"class":6},1]